USP5 and neuroblastoma: Combination therapy with an HDAC inhibitor (SAHA) and a novel pyridobenzimidazole (SE486-11) bound and inactivated USP5 with potent inhibition of tumorigenicity as a novel therapeutic approach for the treatment of MYCN-driven neuroblastoma.